{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:54:58Z","timestamp":1788328498252,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05121-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:45:06Z","timestamp":1779482706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-life effectiveness and safety of lumacaftor\/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre study"],"prefix":"10.1038","author":[{"given":"Santiago","family":"Presti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimbalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Terminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Di Dio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ficili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"De Venuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Adelaide","family":"Calderazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ripani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatello","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"5121_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1891\/NN-2022-0007","volume":"42","author":"H Myer","year":"2023","unstructured":"Myer, H., Chupita, S. & Jnah, A. Cystic fibrosis: back to the basics. Neonatal Netw. NN 42, 23\u201330, https:\/\/doi.org\/10.1891\/NN-2022-0007 (2023).","journal-title":"Neonatal Netw. NN"},{"key":"5121_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann, H. & Ratjen, F. Cystic Fibrosis. N. Engl. J. Med 389, 1693\u20131707, https:\/\/doi.org\/10.1056\/NEJMra2216474 (2023).","journal-title":"N. Engl. J. Med"},{"key":"5121_CR3","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong, T. & Ramsey, B. W. Cystic Fibrosis: A Review. JAMA 329, 1859\u20131871, https:\/\/doi.org\/10.1001\/jama.2023.8120 (2023).","journal-title":"JAMA"},{"key":"5121_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1080\/14656566.2025.2538275","volume":"26","author":"L Santos","year":"2025","unstructured":"Santos, L., Camargo, M., Terlizzi, V. & Lopes-Pacheco, M. Advancing cystic fibrosis treatment: investigational agents on the horizon. Expert Opin. Pharmacother. 26, 1297\u20131310, https:\/\/doi.org\/10.1080\/14656566.2025.2538275 (2025).","journal-title":"Expert Opin. Pharmacother."},{"key":"5121_CR5","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 108, 18843\u201318848, https:\/\/doi.org\/10.1073\/pnas.1105787108 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5121_CR6","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1091\/mbc.E13-05-0240","volume":"24","author":"HY Ren","year":"2013","unstructured":"Ren, H. Y. et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol. Biol. Cell 24, 3016\u20133024, https:\/\/doi.org\/10.1091\/mbc.E13-05-0240 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"5121_CR7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1080\/14740338.2017.1372419","volume":"16","author":"MT Guevera","year":"2017","unstructured":"Guevera, M. T. & McColley, S. A. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Opin. Drug Saf. 16, 1305\u20131311, https:\/\/doi.org\/10.1080\/14740338.2017.1372419 (2017).","journal-title":"Expert Opin. Drug Saf."},{"key":"5121_CR8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Lumacaftor\/Ivacaftor: A Review in Cystic Fibrosis. Drugs 76, 1191\u20131201, https:\/\/doi.org\/10.1007\/s40265-016-0611-2 (2016).","journal-title":"Drugs"},{"key":"5121_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1358\/dot.2016.52.4.2467205","volume":"52","author":"W Zhang","year":"2016","unstructured":"Zhang, W., Zhang, X., Zhang, Y. H., Strokes, D. C. & Naren, A. P. Lumacaftor\/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR. Drugs Today Barc. Spain 1998 52, 229\u2013237, https:\/\/doi.org\/10.1358\/dot.2016.52.4.2467205 (2016).","journal-title":"Drugs Today Barc. Spain 1998"},{"key":"5121_CR10","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2147\/DDDT.S153719","volume":"13","author":"GJ Connett","year":"2019","unstructured":"Connett, G. J. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des. Devel Ther. 13, 2405\u20132412, https:\/\/doi.org\/10.2147\/DDDT.S153719 (2019).","journal-title":"Drug Des. Devel Ther."},{"key":"5121_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1753465815601934","volume":"9","author":"K Kuk","year":"2015","unstructured":"Kuk, K. & Taylor-Cousar, J. L. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther. Adv. Respir. Dis. 9, 313\u2013326, https:\/\/doi.org\/10.1177\/1753465815601934 (2015).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"5121_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating, C. et al. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir. Med 13, 256\u2013271, https:\/\/doi.org\/10.1016\/S2213-2600(24)00411-9 (2025).","journal-title":"Lancet Respir. Med"},{"key":"5121_CR13","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ppul.26535","volume":"58","author":"S Uytun","year":"2023","unstructured":"Uytun, S. et al. Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year? Pediatr. Pulmonol. 58, 2505\u20132512, https:\/\/doi.org\/10.1002\/ppul.26535 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"5121_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","volume":"23","author":"PR Burgel","year":"2024","unstructured":"Burgel, P. R. et al. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 23, 187\u2013202, https:\/\/doi.org\/10.1016\/j.jcf.2024.01.005 (2024).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","volume":"22","author":"KW Southern","year":"2023","unstructured":"Southern, K. W. et al. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 22, 17\u201330, https:\/\/doi.org\/10.1016\/j.jcf.2022.10.002 (2023).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR16","unstructured":"Attivazione web e pubblicazione schede di monitoraggio - Registro ORKAMBI. Accessed September 30, 2025. https:\/\/www.aifa.gov.it\/en\/-\/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-orkambi"},{"key":"5121_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","volume":"206","author":"JH Rayment","year":"2022","unstructured":"Rayment, J. H. et al. A Phase 3, Open-Label Study of Lumacaftor\/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. Am. J. Respir. Crit. Care Med 206, 1239\u20131247, https:\/\/doi.org\/10.1164\/rccm.202204-0734OC (2022).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"5121_CR18","unstructured":"Commissioner O of the. What is a Serious Adverse Event? FDA. Published online May 15, 2024. Accessed October 30, 2025. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"5121_CR19","unstructured":"Serious adverse reaction | European Medicines Agency (EMA). Accessed October 30, 2025. https:\/\/www.ema.europa.eu\/en\/glossary-terms\/serious-adverse-reaction"},{"key":"5121_CR20","doi-asserted-by":"publisher","unstructured":"Terlizzi V. et al. Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least one F508del Allele Receiving Elexacaftor\/Tezacaftor\/Ivacaftor. J Pediatr. Published online June 28, 2024:114176. https:\/\/doi.org\/10.1016\/j.jpeds.2024.114176","DOI":"10.1016\/j.jpeds.2024.114176"},{"key":"5121_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpeds.2007.03.002","volume":"151","author":"VA LeGrys","year":"2007","unstructured":"LeGrys, V. A., Yankaskas, J. R., Quittell, L. M., Marshall, B. C. & Mogayzel, P. J. Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J. Pediatr. 151, 85\u201389, https:\/\/doi.org\/10.1016\/j.jpeds.2007.03.002 (2007).","journal-title":"J. Pediatr."},{"key":"5121_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M. & Littlewood, J. M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 2, 29\u201334, https:\/\/doi.org\/10.1016\/S1569-1993(02)00141-8 (2003).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med 180, 802\u2013808, https:\/\/doi.org\/10.1164\/rccm.200812-1845PP (2009).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"5121_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<172::AID-PPUL3>3.0.CO;2-1","volume":"29","author":"A Cade","year":"2000","unstructured":"Cade, A. et al. Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis. Pediatr. Pulmonol. 29, 172\u2013176 (2000).","journal-title":"Pediatr. Pulmonol."},{"key":"5121_CR25","doi-asserted-by":"publisher","unstructured":"Katz T. et al. Consensus-based guidance for the nutritional management of children with cystic fibrosis on ELEXACAFTOR\/TEZACAFTOR\/IVACAFTOR. J Cyst Fibros Off J Eur Cyst Fibros Soc. Published online February 16, 2026:S1569-1993(26)00033-0. https:\/\/doi.org\/10.1016\/j.jcf.2026.02.004","DOI":"10.1016\/j.jcf.2026.02.004"},{"key":"5121_CR26","doi-asserted-by":"publisher","first-page":"2102398","DOI":"10.1183\/13993003.02398-2021","volume":"60","author":"AC Kentgens","year":"2022","unstructured":"Kentgens, A. C. et al. Normative multiple-breath washout data in school-aged children corrected for sensor error. Eur. Respir. J. 60, 2102398, https:\/\/doi.org\/10.1183\/13993003.02398-2021 (2022).","journal-title":"Eur. Respir. J."},{"key":"5121_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E. et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med 373, 220\u2013231, https:\/\/doi.org\/10.1056\/NEJMoa1409547 (2015).","journal-title":"N. Engl. J. Med"},{"key":"5121_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","volume":"4","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. et al. Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir. Med 4, 617\u2013626, https:\/\/doi.org\/10.1016\/S2213-2600(16)30121-7 (2016).","journal-title":"Lancet Respir. Med"},{"key":"5121_CR29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12251","volume":"12","author":"S Perveen","year":"2020","unstructured":"Perveen, S. et al. How Clinically Efficient Is Lumacaftor\/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review. Cureus 12, e12251. https:\/\/doi.org\/10.7759\/cureus.12251 (2020).","journal-title":"Cureus"},{"key":"5121_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/17512433.2017.1378094","volume":"10","author":"MN Bulloch","year":"2017","unstructured":"Bulloch, M. N., Hanna, C. & Giovane, R. Lumacaftor\/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Expert Rev. Clin. Pharm. 10, 1055\u20131072, https:\/\/doi.org\/10.1080\/17512433.2017.1378094 (2017).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"5121_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","volume":"24","author":"ET Zemanick","year":"2025","unstructured":"Zemanick, E. T. et al. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 24, 246\u2013254, https:\/\/doi.org\/10.1016\/j.jcf.2024.12.006 (2025).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR32","doi-asserted-by":"publisher","unstructured":"Alicandro G. et al. Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry. Pediatr Res. Published online November 14, 2025. https:\/\/doi.org\/10.1038\/s41390-025-04552-6","DOI":"10.1038\/s41390-025-04552-6"},{"key":"5121_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.27473","volume":"60","author":"AM Zwitserloot","year":"2025","unstructured":"Zwitserloot, A. M. et al. Introduction of Ivacaftor\/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study. Pediatr. Pulmonol. 60, e27473. https:\/\/doi.org\/10.1002\/ppul.27473 (2025).","journal-title":"Pediatr. Pulmonol."},{"key":"5121_CR34","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1513\/AnnalsATS.202402-201OC","volume":"21","author":"M Stahl","year":"2024","unstructured":"Stahl, M. et al. Long-Term Impact of Lumacaftor\/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial. Ann. Am. Thorac. Soc. 21, 1550\u20131559, https:\/\/doi.org\/10.1513\/AnnalsATS.202402-201OC (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"5121_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","volume":"12","author":"GM Solomon","year":"2024","unstructured":"Solomon, G. M. et al. Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial. Lancet Respir. Med 12, 947\u2013957, https:\/\/doi.org\/10.1016\/S2213-2600(24)00205-4 (2024).","journal-title":"Lancet Respir. Med"},{"key":"5121_CR36","doi-asserted-by":"publisher","unstructured":"Burgel P. R. et al. Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies. Lancet Respir Med. Published online September 3, 2025:S2213-260000190-00190. https:\/\/doi.org\/10.1016\/S2213-2600(25)00190-0","DOI":"10.1016\/S2213-2600(25)00190-0"},{"key":"5121_CR37","doi-asserted-by":"publisher","unstructured":"Pranke I. et al. Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR. Front Pharmacol. 16:1661417. https:\/\/doi.org\/10.3389\/fphar.2025.1661417","DOI":"10.3389\/fphar.2025.1661417"},{"key":"5121_CR38","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/ppul.26442","volume":"58","author":"V Terlizzi","year":"2023","unstructured":"Terlizzi, V. et al. Lung clearance index in children with cystic fibrosis previously diagnosed with CRMS\/CFSPID: A monocentric prospective experience. Pediatr. Pulmonol. 58, 2124\u20132131, https:\/\/doi.org\/10.1002\/ppul.26442 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"5121_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200911-1646OC","volume":"183","author":"P Aurora","year":"2011","unstructured":"Aurora, P. et al. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am. J. Respir. Crit. Care Med 183, 752\u2013758, https:\/\/doi.org\/10.1164\/rccm.200911-1646OC (2011).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"5121_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcf.2021.06.002","volume":"21","author":"P Reix","year":"2022","unstructured":"Reix, P. et al. Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 21, 155\u2013159, https:\/\/doi.org\/10.1016\/j.jcf.2021.06.002 (2022).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2024.02.004","volume":"23","author":"C Kim","year":"2024","unstructured":"Kim, C. et al. Effectiveness of lumacaftor\/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 23, 436\u2013442, https:\/\/doi.org\/10.1016\/j.jcf.2024.02.004 (2024).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.5863\/1551-6776-25.5.431","volume":"25","author":"EM Stephan","year":"2020","unstructured":"Stephan, E. M. et al. Practitioner Due Diligence: Real-World Lumacaftor\/Ivacaftor Use. J. Pediatr. Pharm. Ther. JPPT J. PPAG 25, 431\u2013436, https:\/\/doi.org\/10.5863\/1551-6776-25.5.431 (2020).","journal-title":"J. Pediatr. Pharm. Ther. JPPT J. PPAG"},{"key":"5121_CR43","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.3390\/jcm13133652","volume":"13","author":"D Salvatore","year":"2024","unstructured":"Salvatore, D., Padoan, R., Amato, A., Salvatore, M. & Campagna, G. On Behalf Of The Italian Cf Registry Working Group null. Nutritional Trends in Cystic Fibrosis: Insights from the Italian Cystic Fibrosis Patient Registry. J. Clin. Med 13, 3652, https:\/\/doi.org\/10.3390\/jcm13133652 (2024).","journal-title":"J. Clin. Med"},{"key":"5121_CR44","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur. Respir. J. 62, 2202153, https:\/\/doi.org\/10.1183\/13993003.02153-2022 (2023).","journal-title":"Eur. Respir. J."},{"key":"5121_CR45","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","volume":"230","author":"EL Ledger","year":"2024","unstructured":"Ledger, E. L. et al. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis. J. Infect. Dis. 230, e536\u2013e547, https:\/\/doi.org\/10.1093\/infdis\/jiae051 (2024).","journal-title":"J. Infect. Dis."},{"key":"5121_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MCP.0000000000000616","volume":"25","author":"ET Zemanick","year":"2019","unstructured":"Zemanick, E. T. & Bell, S. C. Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Curr. Opin. Pulm. Med 25, 636\u2013645, https:\/\/doi.org\/10.1097\/MCP.0000000000000616 (2019).","journal-title":"Curr. Opin. Pulm. Med"},{"key":"5121_CR47","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.chom.2025.07.009","volume":"33","author":"SL Durfey","year":"2025","unstructured":"Durfey, S. L. et al. Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation. Cell Host Microbe 33, 1428\u20131445.e4, https:\/\/doi.org\/10.1016\/j.chom.2025.07.009 (2025).","journal-title":"Cell Host Microbe"},{"key":"5121_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","volume":"22","author":"ML Ramsey","year":"2023","unstructured":"Ramsey, M. L. et al. Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review. J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc. 22, 193\u2013200, https:\/\/doi.org\/10.1016\/j.jcf.2022.08.008 (2023).","journal-title":"J. Cyst. Fibros. J. Eur. Cyst. Fibros. Soc."},{"key":"5121_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.914790","volume":"10","author":"IR McKay","year":"2022","unstructured":"McKay, I. R. & Ooi, C. Y. The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review. Front Pediatr. 10, 914790. https:\/\/doi.org\/10.3389\/fped.2022.914790 (2022).","journal-title":"Front Pediatr."},{"key":"5121_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1656","volume":"9","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi, V. et al. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol. Genet Genom. Med 9, e1656. https:\/\/doi.org\/10.1002\/mgg3.1656 (2021).","journal-title":"Mol. Genet Genom. Med"},{"key":"5121_CR51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","volume":"201","author":"PR Burgel","year":"2020","unstructured":"Burgel, P. R. et al. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Am. J. Respir. Crit. Care Med 201, 188\u2013197, https:\/\/doi.org\/10.1164\/rccm.201906-1227OC (2020).","journal-title":"Am. J. Respir. Crit. Care Med"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05121-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05121-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05121-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:57:14Z","timestamp":1788285434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05121-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":51,"alternative-id":["5121"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05121-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Patients\u2019 parents provided informed consent for participation.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}